Interface Biologics Appoints Sandra Beach Lin to Board of Directors

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the appointment of Sandra Beach Lin to the Board of Directors.

Medical device clears regulatory hurdle in the United States

What began in the Dentistry lab of Professor Paul Santerre more than a decade ago is now Interface Biologics Inc. (IBI) - a privately-held company poised to transform the market for medical devices in the United States.

Interface Biologics announces Licensing Partner AngioDynamics has received FDA Clearance for BioFlo^TM PICC with Endexo^TM Technology

Many strengths and assets that Ontario's diverse life sciences sector has to offer.

Interface Biologics a part of Life Sciences Ontario (LSO) promotional video showcasing the many strengths and assets that Ontario's diverse life sciences sector has to offer.

Interface Biologics Announces $1 Million Investment By Ontario’s Investment Accelerator Fund – Life Sciences

Toronto, Canada, December 6, 2011 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, announces a $1 million investment ...

Interface Biologics announces Licensing Agreement with Navilyst Medical

Toronto, Canada, October 25, 2011 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce ...

Fresenius Medical Care Executes Exclusive Interface Biologics License Agreement

Toronto, Canada, July 12, 2011 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce ...

Interface Biologics Announces New VP Finance

Toronto, Canada, May 31, 2011 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce ...

Interface Biologics Appoints Art Rosenthal to Chairman of its Board of Directors

Toronto, Canada, February 14th, 2011 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce ...

Interface Biologics Financing Deal Gives A New Face to Biomedical Polymer Technology

At work developing transformative biomedical-polymer products, Interface Biologics, a private company, has recently completed a $7M series B financing led by Business Development Bank of Canada in conjunction with Covington Capital and VG Partners.

Interface Biologics - BASF Future Business Collaborate

Toronto, Canada, January 4, 2011 - For Immediate Release

Interface Biologics Inc. (IBI), a privately held commercial stage developer of transformative biomedical-polymer products, is pleased to announce the…

Interface Biologics Receives ISO 13485:2003 Certification

Toronto, Canada, October 26, 2010 – For Immediate Release

Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology…

U of T is helping to create a culture of innovation

Dentistry professor Paul Santerre understands the world of start-up companies. Ten years ago, well before assuming his current role as director of the Institute…

Interface Biologics – Fresenius Medical Care Sign License Agreement

Toronto-- July 20, 2010 --Interface Biologics Inc. (IBI), a privately held early commercial stage developer of transformative biomedical-polymer technology products, is pleased to announce…

Interface Biologics Inc’s Chief Scientific Officer Wins Julia Levy Award

Toronto, Canada, March 5, 2010 - For Immediate Release

Interface Biologics Inc. (IBI), a privately held developer of transformative bio-medical polymer technology that improves the…